Academic Content and Language Evaluation of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (5793)
All Articles published online
|
Publishing Process of This Article
|
Feb 7, 2014 (publication date) through Nov 25, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Krishnareddy S, Swaminath A. When combination therapy isn’t working: Emerging therapies for the management of inflammatory bowel disease. World J Gastroenterol 2014; 20(5): 1139-1146 [PMID: 24574790 DOI: 10.3748/wjg.v20.i5.1139] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v20/i5/1139.htm |
| Number | Citing Articles |
| 1 |
Lindsay Hahn, Ashton Beggs, Kristy Wahaib, Leela Kodali, Vanessa Kirkwood. Vedolizumab: An integrin-receptor antagonist for treatment of Crohn’s disease and ulcerative colitis. American Journal of Health-System Pharmacy 2015; 72(15): 1271 doi: 10.2146/ajhp140449
|
| 2 |
Javier P. Gisbert, María Chaparro. Ustekinumab to treat Crohn's disease. Gastroenterología y Hepatología (English Edition) 2017; 40(10): 688 doi: 10.1016/j.gastre.2017.08.003
|
| 3 |
Raewyn M. Poole. Vedolizumab: First Global Approval. Drugs 2014; 74(11): 1293 doi: 10.1007/s40265-014-0253-1
|
| 4 |
Diego Currò, Gianluca Ianiro, Silvia Pecere, Stefano Bibbò, Giovanni Cammarota. Probiotics, fibre and herbal medicinal products for functional and inflammatory bowel disorders. British Journal of Pharmacology 2017; 174(11): 1426 doi: 10.1111/bph.13632
|
| 5 |
Ryan Marshall, Ian Taylor, Christopher Lahr, Thomas L. Abell, Ingrid Espinoza, Nitin K. Gupta, Christian R. Gomez. Bioelectrical Stimulation for the Reduction of Inflammation in Inflammatory Bowel Disease. Clinical Medicine Insights: Gastroenterology 2015; 8: CGast.S31779 doi: 10.4137/CGast.S31779
|
| 6 |
Javier P. Gisbert, Eugeni Domènech. Vedolizumab en el tratamiento de la enfermedad de Crohn. Gastroenterología y Hepatología 2015; 38(5): 338 doi: 10.1016/j.gastrohep.2014.12.003
|
| 7 |
M. V. Shapina, B. A. Nanaeva, A. V. Vardanyan. EFFICACY AND SAFETY OF USTEKINUMAB FOR CROHN’S DISEASE (review. Koloproktologia 2019; 18(3(69)): 119 doi: 10.33878/2073-7556-2019-18-3-119-130
|
| 8 |
Javier P. Gisbert, María Chaparro. Ustekinumab en el tratamiento de la enfermedad de Crohn. Gastroenterología y Hepatología 2017; 40(10): 688 doi: 10.1016/j.gastrohep.2017.08.006
|